Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 249655
Corporate User License Price USD 4500
Corporate User License Price INR 320985
Site License Price USD 4000
Site License Price INR 285320
Request a Quote

Report Title

Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 4000
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024



Executive Summary

Global Biologics Market-Drivers, Opportunities, Trends, and Forecasts: 2018-2024

Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.

The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth oppurtunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.

Market Analysis: The Global Biologics market is estimated to witness a CAGR of 9.9% during the forecast period 2018-2024. The global market is analyzed based on three segments-Product, Application and regions.

Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.

Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.

Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.

Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.

Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received second FDA approval for Kymriah to treat patients with B-cell lymphoma.

Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Table of Contents

1 Industry Outlook 10

1.1 Industry Overview 10

1.2 Industry Trends 11

1.2.1 R&D pipeline in pharmaceutical industry 11

1.2.2 Top pharma drugs by sales in 2017 (USD Million) 13

2 Report Outline 16

2.1 Report Scope 16

2.2 Report Summary 16

2.3 Research Methodology 17

2.4 Report Assumptions 17

3 Market Snapshot 19

3.1 Market Definition-Infoholic Research 19

3.2 Biologics patent expiration in US and Europe (2010-2020) 19

3.3 Segmented Addressable Market (SAM) 19

3.4 Trends of the biologics market 20

3.5 Related Markets 21

3.5.1 Over the counter drugs 21

3.5.2 Orphan drugs 22

3.5.3 Human Insulin 23

4 Market Outlook 25

4.1 Market segmentation 25

4.2 PEST Analysis 26

4.3 Porter 5(Five) Forces 27

5 Market Characteristics 28

5.1 DRO-Global Biologics Market Dynamics 28

5.1.1 Drivers 28

5.1.1.1 Growing incidence of disease across the globe 28

5.1.1.2 Increasing number of biologics approvals 29

5.1.2 Opportunities 30

5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials 30

5.1.2.2 Increasing opportunities in emerging markets 31

5.1.3 Restraints 32

5.1.3.1 Challenges associated with biologics production 32

5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars 33

5.2 DRO-Impact Analysis 33

5.3 Key Stakeholders 35

6 Products: Market Size & Analysis 36

6.1 Overview 36

6.2 Monoclonal antibodies 37

6.3 Recombinant proteins/Hormones 39

6.4 Vaccines 40

6.5 Cell and Gene Therapy 42

6.6 Others 43

7 Applications: Market Size & Analysis 45

7.1 Overview 45

7.2 Cancer 46

7.3 Immunological disorders 46

7.4 Infectious disease 47

7.5 Hematologic disorders 47

7.6 Cardiovascular disease 48

7.7 Others 48

8 Regions: Market Size and Analysis 49

8.1 Overview 49

8.2 North America 50

8.2.1 US 50

8.2.2 Canada 51

8.3 Europe 51

8.3.1 UK 52

8.3.2 Germany 53

8.3.3 France 53

8.3.4 Spain 53

8.4 Asia Pacific 54

8.4.1 India 54

8.4.2 China 55

8.4.3 Japan 55

8.5 Rest of the World 55

9 Competitive Landscape 57

9.1 Overview 57

10 Vendor Profiles 60

10.1 F. Hoffmann-La Roche 60

10.1.1 Overview 60

10.1.2 Business Unit 63

10.1.3 Geographic Presence 63

10.1.4 Business Focus 64

10.1.5 SWOT Analysis 64

10.1.6 Business Strategy 65

10.2 Sanofi S.A. 66

10.2.1 Overview 66

10.2.2 Business Units 70

10.2.3 Geographic Presence 71

10.2.4 Business Focus 71

10.2.5 SWOT Analysis 72

10.2.6 Business Strategies 72

10.3 Amgen Inc. 73

10.3.1 Overview 73

10.3.2 Geographic Presence 77

10.3.3 Business Focus 77

10.3.4 SWOT Analysis 79

10.3.5 Business Strategies 80

10.4 Novo Nordisk A/S 81

10.4.1 Overview 81

10.4.2 Business Units 84

10.4.3 Geographic Presence 85

10.4.4 Business Focus 85

10.4.5 SWOT Analysis 86

10.4.6 Business Strategies 86

10.5 AbbVie Inc. 87

10.5.1 Overview 87

10.5.2 Geographic Presence 90

10.5.3 Business Focus 90

10.5.4 SWOT Analysis 91

10.5.5 Business Strategies 91

10.6 Johnson & Johnson 92

10.6.1 Overview 92

10.6.2 Business Units 96

10.6.3 Geographic Revenue 96

10.6.4 Business Focus 97

10.6.5 SWOT Analysis 98

10.6.6 Business Strategies 98

10.7 Novartis AG 99

10.7.1 Overview 99

10.7.2 Business Units 102

10.7.3 Geographic Revenue 103

10.7.4 Business Focus 104

10.7.5 SWOT Analysis 104

10.7.6 Business Strategies 105

11 Companies to Watch for 106

11.1 Bristol-Myers Squibb 106

11.1.1 Overview 106

11.2 GlaxoSmithKline plc 108

11.2.1 Overview 108

11.3 Merck & Co. 110

11.3.1 Overview 110

11.4 Eli Lilly and Company Ltd. 111

11.4.1 Overview 111

11.5 Teva Pharmaceutical Industries Ltd. 113

11.5.1 Overview 113

11.6 AstraZeneca PLC 114

11.6.1 Overview 114

11.7 Takeda pharmaceuticals 117

11.7.1 Overview 117

Annexure 120

Acronyms 120

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 11

CHART 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 12

CHART 3 R&D INVESTMENT BY TOP 10 COMPANIES (USD BN) 12

CHART 4 PHARMACEUTICAL DRUGS BY SALES, 2017 14

CHART 5 RESEARCH METHODOLOGY OF GLOBAL BIOLOGICS MARKET 17

CHART 6 GLOBAL BIOLOGICS MARKET REVENUE, 2017-2024 (USD MILLION) 21

CHART 7 SEGMENTATION OF GLOBAL BIOLOGICS MARKET 25

CHART 8 PEST ANALYSIS OF GLOBAL BIOLOGICS MARKET 26

CHART 9 PORTER 5 FORCES ON GLOBAL BIOLOGICS MARKET 27

CHART 10 DRO-IMPACT ANALYSIS OF GLOBAL BIOLOGICS MARKET 33

CHART 11 KEY STAKEHOLDERS 35

CHART 12 GLOBAL BIOLOGICS BY PRODUCT SEGMENTATION, 2017 (%) 36

CHART 13 GLOBAL MONOCLONAL ANTOBODY MARKET FORECAST, 2017-2024 (USD MILLION) 38

CHART 14 GLOBAL RECOMBINANT PROTEIN/HORMONES MARKET FORECAST, 2017-2024 (USD MILLION) 40

CHART 15 GLOBAL VACCINES MARKET FORECAST, 2017-2024 (USD MILLION) 41

CHART 16 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017-2024 (USD MILLION) 43

CHART 17 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017-2024 (USD MILLION) 44

CHART 18 GLOBAL BIOLOGICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 45

CHART 19 GLOBAL BIOLOGICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 49

CHART 20 BIOLOGICS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 50

CHART 21 BIOLOGICS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 52

CHART 22 BIOLOGICS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 (USD MILLION) 54

CHART 23 BIOLOGICS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 56

CHART 24 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 62

CHART 25 F. HOFFMANN.LA ROCHE: BUSINESS UNITS 63

CHART 26 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 63

CHART 27 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 64

CHART 28 SANOFI: OVERVIEW SNAPSHOT 69

CHART 29 SANOFI SA: BUSINESS UNITS 70

CHART 30 SANOFI SA: GEOGRAPHIC PRESENCE 71

CHART 31 SANOFI SA: SWOT ANALYSIS 72

CHART 32 AMGEN INC.: OVERVIEW SNAPSHOT 75

CHART 33 AMGEN INC.: GEOGRAPHIC PRESENCE 77

CHART 34 AMGEN INC: SWOT ANALYSIS 79

CHART 35 NOVO NORDISK: OVERVIEW SNAPSHOT 83

CHART 36 NOVO NORDISK: BUSINESS UNITS 84

CHART 37 NOVO NORDISK: GEOGRAPHIC PRESENCE 85

CHART 38 NOVO NORDISK A/S: SWOT ANALYSIS 86

CHART 39 ABBVIEE INC: OVERVIEW SNAPSHOT 89

CHART 40 ABBVIEE INC.: GEOGRAPHIC PRESENCE 90

CHART 41 ABBVIE INC.: SWOT ANALYSIS 91

CHART 42 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 95

CHART 43 JOHNSON & JOHNSON: BUSINESS UNITS 96

CHART 44 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 96

CHART 45 JOHNSON & JOHNSON: SWOT ANALYSIS 98

CHART 46 NOVARTIS AG: BUSINESS UNITS 102

CHART 47 NOVARTIS AG: GEOGRAPHIC REVENUE 103

CHART 48 NOVARTIS AG: SWOT ANALYSIS 104

Tables

TABLE 1 PHARMA DRUGS BY SALES, 2017 13

TABLE 2 GLOBAL BIOLOGICS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 49

TABLE 3 OTHER PROMINENT VENDORS OF BIOLOGICS MARKET 59

TABLE 4 F. HOFFMANN-LA ROCHE: OFFERINGS 60

TABLE 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 60

TABLE 6 SANOFI.: OFFERINGS 66

TABLE 7 SANOFI: RECENT DEVELOPMENTS 67

TABLE 8 AMGEN INC.: OFFERINGS 73

TABLE 9 AMGEN INC.: RECENT DEVELOPMENTS 74

TABLE 10 NOVO NORDISK A/S: OFFERINGS 81

TABLE 11 NOVO NORDISK A/S: RECENT DEVELOPMENTS 82

TABLE 12 ABBVIE INC.: OFFERINGS 88

TABLE 13 ABBVIE INC: RECENT DEVELOPMENTS 88

TABLE 14 JOHNSON & JOHNSON: PRODUCT OFFERINGS 92

TABLE 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 93

TABLE 16 NOVARTIS AG: PRODUCT OFFERINGS 99

TABLE 17 NOVARTIS AG: RECENT DEVELOPMENTS 100

TABLE 18 NOVARTIS AG: OVERVIEW SNAPSHOT 102

TABLE 19 BRISTOL-MYERS SQUIBB: SNAPSHOT 106

TABLE 20 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 107

TABLE 21 GLAXOSMITHKLINE PLC.: OVERVIEW 108

TABLE 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 109

TABLE 23 MERCK & CO: OVERVIEW 110

TABLE 24 MERCK & CO: RECENT DEVELOPMENTS 110

TABLE 25 ELI LILLY AND COMPANY: SNAPSHOT 112

TABLE 26 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 112

TABLE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 113

TABLE 28 TEVA PHARMACEUTICAL: RECENT DEVELOPMENTS 113

TABLE 29 ASTRAZENECA PLC: SNAPSHOT 115

TABLE 30 ASTRAZENECA PLC: RECENT DEVELOPMENTS 115

TABLE 31 TAKEDA PHARMACEUTICALS: SNAPSHOT 117

TABLE 32 TAKEDA PHARMACEUTICALS: RECENT DEVELOPMENTS 118

F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person